Approval · Notice of Compliance 6817 · 2005

SINGULAIR: Notice of Compliance 6817

Issued May 16, 2005

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 6817
Date: May 16, 2005
Company: Merck Frosst Canada Ltd., Merck Frosst Canada Ltée
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Manufacturer name change
Therapeutic class: Leukotriene receptor antagonist

Products in this notice

Brand	DIN	Status today
SINGULAIR	02247997	Cancelled Post Market
SINGULAIR	02243602	Marketed
SINGULAIR	02238216	Marketed
SINGULAIR	02238217	Marketed

Medicinal ingredients

MONTELUKAST SODIUM 4 MG per 500MG
MONTELUKAST SODIUM 4 MG per TAB
MONTELUKAST SODIUM 5 MG per TAB
MONTELUKAST SODIUM 10 MG per TAB